Status:
COMPLETED
Post Marketing Surveillance Study of Dysport
Lead Sponsor:
Ipsen
Conditions:
Blepharospasm
Hemifacial Spasm
Eligibility:
All Genders
2+ years
Brief Summary
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
Eligibility Criteria
Inclusion
- adult or child over the age of 2 years
- scheduled to receive Dysport as per their normal treatment practice, and in conformance with their country's Summary of Product Characteristics
Exclusion
- history of hypersensitivity to Dysport or drugs with a similar chemical structure
- treatment with any other investigational drug within the last 30 days before survey entry
Key Trial Info
Start Date :
October 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
783 Patients enrolled
Trial Details
Trial ID
NCT00210431
Start Date
October 1 2004
End Date
June 1 2006
Last Update
March 31 2020
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Saint Esprit
Agen, France, 47923
2
Center Hospitalier du Pays d'Aix
Aix-en-Provence, France, 13616
3
Centre Hospitalier
Chambéry, France, 73011
4
Hopital Timone Adultes
Marseille, France, 13385